Navigation Links
NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
Date:4/22/2009

ce, they have published successful results of a Phase II clinical trial in ear infections (otitis externa) using NCT. NovaBay expects Alcon, its licensee for the use of Aganocide compounds in the treatment of eye, ear, and sinus infections, to start human trials in the ear during 2009 with NovaBay's lead Aganocide compound NVC-422. Professors Nagl and Gottardi have also pursued studies with NCT in additional indications that can provide NovaBay with guidance in its future clinical programs.

In addition to the research agreement, NovaBay has obtained an exclusive license to a broad portfolio of intellectual property covering uses of NCT compounds. As a result, NovaBay has augmented its composition of matter patent for Aganocide compounds with a license to a series of patents covering key potential uses, including utility of NCT compounds in pulmonary diseases and their potential use in major animal health markets, such as mastititis.

"We are very excited to collaborate with this world-class research team, and pleased to draw on the extensive experience of Professors Gottardi and Nagl in understanding the role of our class of molecules in the prevention and treatment of infectious diseases," said Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay. "We look forward to building on their work to further expand the range of clinical opportunities provided by our Aganocide compound platform."

"We expect to substantially broaden NovaBay's efforts by leveraging the resources and expertise at the Medical University of Innsbruck," said Dr. Bez Khosrovi, Vice President of Research and Development at NovaBay. "We see this collaboration as adding significant depth to our preclinical and clinical development programs and to the continued exploration of the properties of our Aganocide compounds. We expect that our joint efforts will provide important information that may further accelerate our efforts to develop
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Patterson Medical, ... (Nasdaq: PDCO ), is now an independent ... acquisition of Patterson Medical by Madison Dearborn Partners ... its name for a transition period before rebranding ... and sports medicine products.  With the focused resources ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... to their offering. Developed by Novo ... Novolog) is an important drug for the treatment ... as a fast- acting insulin analog, starts working ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... 2011 Cardinal Health today announced that its board of directors ... on April 15 to shareholders of record on April 1. This ... About Cardinal Health Headquartered in ... a $99 billion health care services company that improves ...
... ANGELES, Feb. 1, 2011 A breakthrough in stroke ... in stroke survivors has published today. In the February ... the first human results of a new method ... reported. Rapid improvement in impaired motor function, gait, hand ...
Cached Medicine Technology:Cardinal Health Declares Regular Quarterly Dividend 2Inflammation Identified as New Therapeutic Target Years After Stroke 2
(Date:8/28/2015)... ... 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance ... A Mission” benefit concert in Mendon, IL. Held in the Show Barn at the ... music education programs in the underfunded local school districts of Mendon at neighboring Quincy, ...
(Date:8/28/2015)... ... 28, 2015 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices, recently released Visio Stencils for the following product ... Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems Virtual ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF International ... adolescent residential, counseling, day treatment and intensive family based services. , By pursuing ... quality and its pursuit of excellence. As a nonprofit charity for more than ...
(Date:8/28/2015)... ... , ... Northridge dentists Dr. Elyson and Dr. Assili are now ... currently receive a one hour treatment of this teeth whitening option. Zoom whitening ... of unique features that can turn teeth up to nine shades whiter. Effective on ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... which is dedicated to distributing health information technology innovation to transform quality and ... Results of the survey will be de-identified and aggregated before being publicly shared ...
Breaking Medicine News(10 mins):Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2
... , , ... an effort to help brokers, employers and employees reap the ... carbon footprint, The Guardian Life Insurance Company of America ... and small businesses, is launching a campaign focusing on its ...
... the University of Helsinki, Finland, and the Paul Scherrer ... structure of the ligand binding domain of a vascular ... of its ligands (VEGF-C). Cancer cells require access ... metastasis. By releasing VEGFs, cancer cells stimulate the surrounding ...
... the amount teenage minority boys smoke but does not ... a new study from the Indiana University School of ... March 2010 issue of the American Journal of ... under "First Look" at http://ajph.aphapublications.org/first_look.shtml . While ...
... study finds, , TUESDAY, Jan. 19 (HealthDay News) -- The more ... it, a new study finds. , The finding came from a ... diet plans. The simpler plan provided shopping lists for dieters and ... assigned point values to every food and instructed participants to eat ...
... EET Reno is ... of a Rapid Prototyping line increases the flexibility and services available to its new and ... (PRWEB) January ... high speed Rapid Prototyping line for its plant in Reno, Nevada. This strategic addition ...
... ... rapidly-growing network of retailers carrying its over-the-counter (OTC) pain reliever, Cobroxin, by expanding ... national sponsorships, and additional print advertising. , ... Delray Beach, FL (Vocus) January 19, 2010 ...
Cached Medicine News:Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 2Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 3Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 4Health News:Minority teen boys smoke more when they perceive discrimination; girls do not 2Health News:Complex Weight-Loss Plans Erode Dieters' Resolve 2Health News:EE Technologies Adds High Speed Rapid Prototyping Line in Reno 2Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 2Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 3Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 4Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 5
Guthrie fixation hook, sharp double prongs....
... lenses will feel good when you first put ... 12 hours later? Many lenses start to feel ... look blurry. But with Proclear lenses, youll enjoy ... This exceptional level of comfort is made possible ...
Designed to allow very easy handling....
The convenience of disposable type lenses available in a wide variety of options. Recommended replacement schedule: one week for extended wear, two weeks for daily wear....
Medicine Products: